Oxbryta cost per signed retainer
Oxbryta (sickle cell disease) carries a cost per signed retainer of $5,800–$8,400 in Q1 2026, current as of March 31, 2026, at a 6–9% signed rate and a very high qualification tier. The litigation is active. Sample size and confidence interval for this row are not available; the reason is stated on each figure below rather than omitted.
Data as of Updated Q1 2026 release
CPR range · Q1 2026
$5,800 – $8,400
Median: n/a — Per-tort medians are not published. The dataset carries the interquartile low and high bounds for each tort; only the national median is published as a point value.
Signed rate
6–9%
Share of exclusive leads that become signed retainers.
Qualification tier
Very High
Relative difficulty of clearing this tort's qualifying criteria.
Status
Active
As published in the Q1 2026 release.
Sample size
n/a
Per-tort sample sizes are not broken out in the published dataset. The panel total (140 firms, $180M of annual mass tort lead spend across 16 active tort categories) is published at the panel level only, so the number of firms and the spend basis behind any single row cannot be stated.
Confidence interval
n/a
Not computable from the published dataset. Benchmarks are published as trimmed interquartile ranges, and the per-observation values a confidence interval requires are not retained in the published figures.
Unverified
No third party has reviewed this methodology or the underlying data. Mass Tort Marketing Agency sells the leads these figures price.
What third-party verification would involveOxbryta CPR over time
The series for Oxbryta starts at Q1 2026. Mass Tort Marketing Agency holds one published quarter of per-tort data for this tort, so there is no trend line to draw yet — the single point is shown below, and a second point will appear when the next quarter publishes.
| Quarter | CPR low | CPR high | Note |
|---|---|---|---|
| Q4 2024 | n/a | n/a | No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026. |
| Q1 2026 | $5,800 | $8,400 | Published. |
What qualifies a Oxbryta claimant
Documented Oxbryta (voxelotor) use plus a documented vaso-occlusive crisis hospitalization or wrongful death.
Falloff: n/a — Not published for this tort. The source dataset does not state a numeric falloff range for Oxbryta.
Active — what that means for acquisition
Active post-withdrawal tort — Pfizer voluntarily withdrew voxelotor in September 2024 following safety concerns around vaso-occlusive crises and mortality signals. Signed rates reflect both the narrow claimant pool and the demographic concentration of sickle cell disease patients. Paid-digital acquisition alone is inefficient here; firms building relationships with sickle cell disease advocacy organizations and hematology practices in the Southeast and mid-Atlantic typically operate at $4,000-$5,500 CPR, well below paid-digital-only firms.
Oxbryta cost per lead
This dataset does not publish a cost-per-lead figure for Oxbryta, and no CPL value is shown here rather than being derived from the CPR band. The two are related by the signed rate — CPL is approximately CPR × signed rate — but running that multiplication against a published interquartile band produces a number that looks measured and is not, so it is left out. What the benchmark does state is the signed rate: 6–9% of exclusive Oxbryta leads become signed retainers that survive the 30-day falloff window. If you have your own CPL from a vendor quote, that signed rate is the multiplier that turns it into a comparable CPR.
Download this row
How to cite this page
Suggested citation:
Mass Tort Marketing Agency. "Oxbryta (sickle cell disease) cost per signed retainer." Q1 2026 CPR Benchmark, published April 24, 2026. https://www.masstortmarketingagency.com/benchmarks/oxbryta
- Canonical URL:
- https://www.masstortmarketingagency.com/benchmarks/oxbryta
- License:
- CC BY 4.0 — reuse permitted with attribution to Mass Tort Marketing Agency CPR Benchmark, https://www.masstortmarketingagency.com/benchmarks/
Citing a number that must stay stable? Point at a dated snapshot instead of the live page — snapshot files never change.